Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T41202
(Former ID: TTDI00186)
|
|||||
| Target Name |
microRNA hsa-miR-29b (MIR29b)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Keloid/hypertrophic scar [ICD-11: EE60] | |||||
| BioChemical Class |
Non-coding RNA target
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Remlarsen | Drug Info | Phase 2 | Keloid | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Replacement | [+] 1 Replacement drugs | + | ||||
| 1 | Remlarsen | Drug Info | [3] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | miR-29b contributes to multiple types of muscle atrophy. Nat Commun. 2017 May 25;8:15201. | |||||
| REF 2 | ClinicalTrials.gov (NCT03601052) Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids. U.S. National Institutes of Health. | |||||
| REF 3 | A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019 May;139(5):1073-1081. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.